Search

Displaying results 1181 - 1190 of 10000 in total
  1. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. … various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures [FDA Label].

    Products: EPO STADA 3333 IU/ML, EPO STADA 10000 IU/ML
  2. Drug

    Menthyl salicylate

    go.drugbank.com/drugs/DB11201
    Approved

    Menthyl salicylate is an ester of menthol and salicylic acid [L2808]. This product is used to treat minor aches and pains of the muscles/joints (e.g., arthritis, backache, sprains) [L2810].

    Mixtures: Dr. Ds Super 7 Pain Relief
  3. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas … Zolbetuximab (previously claudiximab)[A264748] is a chimeric cytolytic antibody comprising variable regions derived from mouse anti-human claudin-18 isoform 2 monoclonal antibody and constant regions derived

  4. Drug

    Setmelanotide

    go.drugbank.com/drugs/DB11700
    ApprovedInvestigational

    [L24474] It is an agonist of the melanocortin 4 receptor. … [A224449] Patients taking setmelanotide experienced an average weight loss of 0.6 kg/week.

  5. Drug

    Varenicline

    go.drugbank.com/drugs/DB01273
    ApprovedInvestigational

    Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015. … Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor.

  6. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    [L10403] and is unique from other drugs used to treat sickle cell anemia, such as [hydroxyurea], [L-glutamine], and [crizanlizumab][A188135,A188138] due to its novel mechanism of action. … Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease.

  7. Drug

    Cinnarizine

    go.drugbank.com/drugs/DB00568
    ApprovedInvestigational

    Cinnarizine could be also viewed as a nootropic drug because of its vasorelaxating abilities (due to calcium channel blockage), which happen mostly in brain. … Combination use of cinnarizine with other nootropics, such as [piracetam] resulted in enhanced effect of boosting brain oxygen supply.

  8. Drug

    Hexaminolevulinate

    go.drugbank.com/drugs/DB06261
    ApprovedInvestigational

    of a prior cystoscopy. … Karl Storz Photodynamic Diagnostic D-Light C (PDD) System for cystoscopic detection of non-muscle invasive papillary cancer of the bladder for patients suspected or known to have lesion(s) on the basis

  9. Drug

    Ceftizoxime

    go.drugbank.com/drugs/DB01332
    ApprovedWithdrawn

    The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. … A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository.

  10. Drug

    Lindane

    go.drugbank.com/drugs/DB00431
    ApprovedWithdrawn

    In Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical … Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment.

    Categories: Compounds used in a research, industrial, or household setting